I Seven healthy male volunteers received a single oral dose of 5 mg, 10 rag, or 20 mg of d-amphetamine. Urine was collected at 2, 4, 8, 12, 18, and 24 h post-dose. Total urine volume was measured, and pH and creatinine were determined. All specimens were analyzed by TDx Amphetamine/Methamphetamine II (TDx), Emit-d.a.u. Monoclonal Amphetamine/Methamphetamine (EM), and Emit II Amphetamine/Methamphetamine (Ell) immunoassays at a cutoff value of 1000-ng/mL amphetamine. Quantitation of urinary amphetamine in all specimens was performed by gas chromatography-mass spectrometry. All urine testing results by the three immunoassays, EM, Ell, and TDx, were in agreement; there were no discordant findings. Of the 42 total urine specimens collected following a 5-mg dose of amphetamine, only 8 (19%) screened positive by immunoassay. Twenty-four of 36 (67%) urine specimens yielded positive responses following a 10-rag dose, and 37 of 42 (88%) were positive by immunoassay following a 20-rag dose. These data demonstrate the present guideline for regulated forensic urine drug testing (FUDT) for amphetamine with a screening cutoff of 1000 ng/ml, is too high to consistently detect the administration of a single 5-rag oral dose of d-amphetamine. There was considerable overlap of amphetamine concentrations in individual specimens following the various doses. Peak urinary amphetamine ranged from 620 to 3160 ng/mL following 5-rag doses. The time to peak concentration also varied widely at each dose, occurring in urines collected 2 to 18 h post-administration. The mean percent of dose excreted as unchanged amphetamine over 24 h at each dose ranged from 35 to 44%. The data demonstrated that amphetamine excretion increases with increasing urine flow and decreasing urine pH. Thus, a positive FUDT result for amphetamine means only that the individual was administered or self-administered amphetamine at some time prior to collection of the specimen.
Introduction Materials and Methods
In 1935, amphetamine was first used clinically as a central 
Subjects and study protocol
Seven healthy volunteers participated in the study. The demographics of the subjects are presented in Table I . All subjects were within +15% of desirable body weight (11) . They had no history of renal, hepatic, cardiovascular, gastrointestinal, neurological, pulmonary, or hematologic disease; drug or alcohol abuse; or psychiatric illness. Each subject passed a physical examination demonstrating no evidence of active disease, and displayed no clinically significant abnormal serum chemistries, hematological findings, or urinalysis results. They had no significant abnormalities on a 12-lead EKG. Subjects had not taken medications chronically for a month and had not taken any medications, including caffeine and alcohol, for 72 h prior to entering the study. All subjects were non-smokers and had negative findings on urine-drug and breath-alcohol tests. Each signed a written consent form before the start of study.
The amphetamine dose study was divided into four periods. Subjects were housed in a study facility the evening before dosing until the day after the collection of the 24-h specimen. Subjects were fasted from midnight on the evening before d-amphetamine or placebo administration until after the 4-h urine specimen was collected. Only water was permitted during the fasting period. Repeated 2-g oral doses of ammonium chloride were administered at 4-h intervals from 12 h prior to and 18 h after d-amphetamine or placebo administration. Each subject received one of four treatments: a single oral dose of 5 rag, 10 rag, or 20 mg of d-amphetamine or a placebo. Both the subject and the investigator were blinded to treatment. Capsules were ingested with 240 mL of water.
Subjects voided prior to dosing, then urine was collected at 2, 4, 8, 12, 18 and 24 h post-dose. Total urine volume was measured and pH determined using a pH meter, and two 25-mL aliquots were frozen until analysis. Each subject drank 120 mL of water 1 h prior to and each hour for 4 h after dosing, after which time water was available ad lib. After collection of 4-h specimen, lunch was served, and dinner was served after the 10-h specimen. The pH of each specimen was noted at the time of collection. Urinary creatinine was determined by colorimetry in a Beckman Astra Analyzer (Brea, CA) following the manufacturers protocol (12) . This study protocol was approved by the Institutional Review Board, Medical College of Virginia.
Immunoassays
TDx. All reagents necessary for the TDx assay were purchased from Abbott Laboratories (Abbott Park, IL). The TDx Amphetamine/Methamphetamine II assays were performed in an Abbott TDx analyzer with 3.03 version software (13) . The calibration curve for the assay was constructed with six calibrator solutions supplied with the assay consisting of d-amphetamine concentrations of 0, 150, 300, 1000, 3000, and 8000 ng/mL. TDx controls of 500, 1500, and 4000 ng/mL d-amphetamine were obtained from Abbott Laboratories. All TDx assay reagents were stored refrigerated at l~ A positive result was a reading of 1000 ng/mL or greater. Emit. All reagents necessary for the Emit-d.a.u. Monoclonal Amphetamine/Methamphetamine Assay (EM) and Emit II Amphetamine/Methamphetamine Assay (EII) assays were obtained from Syva Company (Palo Alto, CA): EMIT ~ antibody/substrate reagent A and enzyme reagent B and EMIT drug assay buffer concentrate. All immunoassay reagents were stored refrigerated at 2~ EM assays were performed on a Syva ETS analyzer with 3.02 version software (14) . The EM assay was calibrated with negative, cutoff, and medium calibrators containing 0.0, 1000, and 5000 ng/mL of d-methamphetamine, respectively. All EII assays (15) were performed on a Hitachi 717 automatic analyzer (Boehringer Mannheim, Indianapolis, IN). The analyzer was calibrated with 0-, 1000-, and 3000-ng/mL d-methamphetamine calibrators, with 1000 ng/mL being the cutoff calibrator. Control urines containing 0, 800, 1000, and 1200 ng/mL d-amphetamine and 0, 800, and 1200 ng/mL d-methamphetamine were included in each batch of specimens. For both Emit assays a rate equal to or greater than the cutoff calibrator was considered a positive result.
In order to determine possible methodological bias between the various immunoassays and GC-MS results, TDx and Emit calibrators and low-positive urine controls were analyzed in duplicate by GC-MS. Results were within + 10% of the labeled values.
GC-MS
Calibrators and controls. A reference standard of 1.0-mg/mL d-amphetamine in methanol was purchased from Radian Corp. (Austin, TX). From this solution, calibrators of 200, 500, 1000, 2000, 4000, 6000, and 8000 ng/mL were prepared in drug-free urine. The internal standard (IS) was amphetamine-ds, 100 tJg/mL in methanol (Radian). This was diluted to 10 pg/mL with methanol to obtain the working IS solution. Urine controls of 1000-and 4000-ng/mL d-amphetamine (Sigma Corp., St Louis MO) were prepared separately with drug-free urine. Drugfree urine used for the preparation of GC-MS calibrators was collected from laboratory personnel and was free of the analytes of interest. Caffeine and nicotine and their metabolites were present in some specimens.
Extraction. Amphetamine was extracted and derivatized as previously described (16) . Briefly, 100 IJL of internal standard was added to 2.0 mL of urine that was made basic by the addition of ammonium hydroxide, then 4.0 mL of chlorobutane was added. This mixture was rotoracked and centrifuged. Three milliliters of chlorobutane was removed and evaporated to approximately 2 mL under air at room temperature. One-hundred microliters of PFPA was added to the chlorobutane; the tube was capped and heated in a dry heat block at 70~ for 15 rain. The mixture was allowed to cool and then evaporate to dryness under air at room temperature. The residue was dissolved in 50 1JL of ethyl acetate and injected into the GC-MS.
GC-MS conditions. GC-MS analyses were performed using a Hewlett Packard (Avondale CA) model 5890 GC coupled to a model 5971A mass selective detector (MSD). Data processing was performed with a Chemstation (version 3.0 software). The column was a 12-m x 0.2-mm capillary HP-1 column. The injector temperature was set at 250~ The oven was initially set at 180~ for 2 rain, then increased 10~ until the final temperature was 250~ Under these conditions, the retention time of amphetamine was 3.9 to 4.0 rain. The MSD was operated in the SIM mode. Ions monitored were m/z 91, 118, and 190. The deuterated internal standard was monitored at m/z 96, 123, and 194 . Each run of specimens on the GC-MS was prefaced by a non-extracted 2.0-pg/mL standard and a solvent blank. Each patient run began and ended with analysis of control specimens.
Results
All positive and negative urine testing results by the three im- were no discordant findings, the term "immunoassay" is used in Tables II-IV, rather than list the same result separately by   each immunoassay.  The results of the 5-rag dose study are summarized in Table  II . Subjects display a wide range in peak urine concentrations, times to peak concentration, and percent of dose of the parent drug excreted within 24 h. Only four of the seven subjects had specimens with amphetamine exceeding the federally mandated FUDT cutoff value of 1000 ng/mL. Of the 24 urines collected from these four subjects, only 8 (33%) contained sufficient concentrations to screen positive for amphetamine by all three immunoassays. The excretion pattern of one of the subjects failing to yield a positive immunoassay result is presented in Figure 1 . This subject's peak urinary amphetamine concentration occurred in the 2-h specimen. The concentration in the 18-h urine exceed that of the preceding 12-h specimen, demonstrating the difficulties of interpreting amphetamine urine concentrations as to the time of ingestion. When the data were normalized to urinary creatinine, peak excretion occurred at 4 h and steadily declined o from that time (Figure 1 ). Of the 42 urines spec-2 imens collected from all 7 of the subjects, only 2 8 (19%) screened positive for amphetamine by 3 1 immunoassay. These data demonstrate the pre-0 sent guideline for regulated FUDT (3,4) for o amphetamine screening at a cutoff of 1000 ng/mL is too high to consistently detect the administration of 5-rag doses of d-amphetamine.
The results of the 10-rag dose study are summarized in Table III . Compared with the 5-rag dose data, subjects displayed much less variance in the peak urinary amphetamine concentration, which ranged from 1960 to 3120 ng/mL. 4 The time to peak urine concentration generally 4 occurred within 2 or 4 h of administration, but 5
was delayed for as long as 12 h in one subject 5 ( Figure 2 ). However, when this subject's data 4 was normalized to creatinine, the peak concen--tration occurred at 4 h and excretion steadily de-2 clined with time ( Figure 2 ). The mean percent of dose excreted as parent drug following 10-rag doses, 42 • 5%, was similar to the mean in the 5-rag dose study, 44 • 6.7%. Five of the six subjects had at least four of their six urine specimens yield positive results by the immunoassays. However, one subject had only two immunoassay-positive urines. In all, 24 of 36 6 (67%) urines collected following a 10-rag dose 4
yielded positive responses. 6 The results of the 20-rag dose study are pre- 6 sented in Table IV . The peak urinary ares phetamine concentration and time to peak 5 concentration varied widely between the subs jects, ranging from 1510 to 4430 ng/mL and 2 to 18 h, respectively. A smaller percentage of the dose as parent amphetamine was recovered within 24 h, 35 + 5%, as compared to the 5-and 10-rag dose studies. All urines collected from three of the subjects yielded positive amphetamine results by the immunoassays. In all, 37 of 42 (88%) were positive by immunoassay. The pH and total volume of each urine were determined. Our data are consistent with the observations of others that amphetamine excretion increases with increasing urine flow and decreasing urine pH (7) (8) (9) (10) . The urinary excretion pattern of subject E in the 20-rag dose study exemplified these relationships (Figure 3) . The peak urine concentration was observed in the 18-h specimen ( Figure 3A) ; however, a pattern of generally decreasing excretion was observed when normalized to creatinine ( Figure 3B ). The data for the 8-h specimen dramatically demonstrates that urinary pH is the single most important factor in amphetamine excretion. The lowest amphetamine concentration was observed in this urine that was collected over the time period of the greatest urinary flow and, hence, largest urine volume ( Figure 3B ). However, this urine was the most alkaline of the specimens from subject E ( Figure 3A) . Thus, despite the large urinary volume output, the high urinary pH allowed for renal tubular absorption, resulting in a low concentration of amphetamine.
Discussion
When urine is acidified the excretion of unchanged amphetamine is approximately four times that of the deaminated metabolites, hippuric and benzoic acid. However, when urine is alkaline, the excretion of these metabolites is approximately equal to that of the unchanged drug (7, 8) . Renal clearance of amphetamine is also dependent on urine flow (8) . When urinary pH is between 5 and 6, renal clearance is only half as efficient at less then 30 mL/h urine flow as when the flow is 30-125 mL/h (10) . All subjects in this study maintained a urinary flow rate exceeding 30 mL/min. Beckett and Rowland (7) have observed the rate of urinary excretion of amphetamine is directly proportional to the plasma concentration when urine is maintained under acidic conditions. This is due to ion trapping in the renal tubules (8) A "" Rowland (7) asserted that renal clearance is related only to glomerular filtration rate. The presented data is consistant with the previously reported relationship between urinary flow and amphetamine excretion (9, 10) .
In reviewing our cumulative data, a relationship between amphetamine dose and resultant urinary concentrations was generally present over the 24-h collection period. Generally, all previous studies of amphetamine excretion administered 10-rag oral doses, which resulted in urine concentrations of 400-4000 ng/mL (7) (8) (9) (10) . In our study, subject urines typically contained less than 1000 ng/mL of amphetamine after 5-rng doses. After 10-rag doses, urinary concentration ranged from 1000 to 2000 ng/mL amphetamine, whereas 20-rag doses yielded concentrations of 2000-4000 ng/mL. However, there was considerable overlap of the amphetamine concentrations in individual specimens following the various doses. For example, following 5-rag doses, two subjects had peak amphetamine urine concentrations that were equal to or greater than peak values observed in urines collected following 10-rag doses. These two 5-rag dose peak urine concentrations also exceeded the peak values observed in two subjects after a 20-rag dose. Therefore, although our data can be manipulated by pharmacokinetic calculations to establish a relationship between amphetamine dose and the mean urinary amphetamine concentrations at various times within 24 h of administration, in terms of FUDT of a single random specimen, we conclude that no precise estimate of dose is possible. For interpretation of FUDT results, our data may support the statement that 1000--4000 ng/mL urinary amphetamine is "consistent" with ingestion of 5 to 20 mg amphetamine within 24 h of administration. However, it should be noted that these concentrations are also consistent with values observed 6 days after cessation of 6000-rag daily doses of amphetamine orally administered for 6 months (18) . Additionally, our data were from a single-dose study and did not address the issue of urine concentrations that may be observed following chronic administration of the drug. For example, urinary d-amphetamine concentrations in random specimens collected from an adult at steady-state receiving 30-rag doses ranged from 1100 to 17,800 ng/mL (19) .
The time to peak urine amphetamine concentration varied widely in each of our dose studies, occurring in urines collected at 2 to 18 h post-administration. When normalized to creatinine excretion, the expected patterns of declining amphetamine concentrations with time were generally obtained. However, our data do demonstrate that within 24 h of amphetamine administration, interpretations of FUDT results from a single random specimen as to the time of amphetamine administration or multiple dosages must be made very carefully. A second urine specimen collected within a 24-h post-administration period may reasonably yield an amphetamine concentration greater than the concentration of a previously collected specimen. Such a finding does not establish that administration of additional amphetamine has occurred.
The mean percent of dose excreted as unchanged amphetamine over 24 h in each of our dose studies ranged from 35 to 44%. Even though we attempted to maintain acidic urine pH by administration of ammonium chloride, the ingestion of lunch and dinner and free access to non-alcoholic beverages during the collection period resulted in fluctuations in urinary pH ( Figure 3A) . The content of these meals was chosen to avoid large quantities of food potentially promoting alkalization of the urine (such as milk, nuts, vegetables, and fruit). The observed fluctuations in urinary pH demonstrates the difficulty of controlling urinary pH in the real-life situation of eating and drinking.
Conclusion
This study demonstrates that the present guideline for regulated FUDT (3, 4) for amphetamine screening at a cut-off of 1000 ng/mL is unlikely to detect the administration of a single 5-rag dose of d-amphetamine, and only more likely than not suitable to detect administration of a 10-rag dose. Additionally, the profound effects of urine pH on urinary excretion of d-amphetamine make any interpretation of FUDT results of 4000 ng/mL or less very tenuous as to ingested dose or time of administration. Thus, a positive FUDT result for amphetamine means only that at some time prior to collection of the specimen the individual was administered or self-administered amphetamine.
